SUNIL BABU M.D.
Prescription History 1891968301
Internal Medicine - Medical Oncology in Fort Wayne, IN


Quality Rating: 85.18 out of 100 score

NPI Status: Active since April 04, 2008

Contact Information

7910 W JEFFERSON BLVD STE 108
FORT WAYNE, IN
ZIP 46804
Phone: (260) 484-8830
Fax: (260) 483-1911

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SUNIL BABU M.D., an active Medical Oncology specialist practicing in Fort Wayne, IN. Our medical registry currently tracks 23 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 592 documented patient claims. Among these therapy options, the most frequently utilized medication is Letrozole, which accounts for 59 claims alone.


Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 450
IN State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills34.1
Peer Average Days Supply1,010
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.5% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,991.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,132.78

State Avg Cost Per Claim

$3,532.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Acyclovir

Generic Formulation: AcyclovirSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 36
30-Day Fills 75.0
Days Supply 2,250
IN State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills38.0
Peer Average Days Supply1,004
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 56.5% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $865.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.03

State Avg Cost Per Claim

$23.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Allopurinol

Generic Formulation: AllopurinolSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 16.0
Days Supply 480
IN State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills130.5
Peer Average Days Supply3,833
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.8% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $81.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.82

State Avg Cost Per Claim

$15.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.

Therapeutic Applications

Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 35
30-Day Fills 93.0
Days Supply 2,790
IN State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills154.1
Peer Average Days Supply4,562
Conservative Utilization

This provider writes prescriptions for this formulation 47.0% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $710.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.30

State Avg Cost Per Claim

$26.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Brukinsa

Generic Formulation: ZanubrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 55
30-Day Fills 55.0
Days Supply 1,650
IN State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.5
Peer Average Days Supply494
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 243.8% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $821,085.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,928.84

State Avg Cost Per Claim

$13,344.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia). Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
IN State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.4
Peer Average Days Supply669
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $181,130.85 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,062.83

State Avg Cost Per Claim

$14,461.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 25.4
Days Supply 691
IN State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills30.5
Peer Average Days Supply409
Conservative Utilization

This provider writes prescriptions for this formulation 35.7% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $527.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.29

State Avg Cost Per Claim

$16.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 55
30-Day Fills 69.0
Days Supply 2,070
IN State Average Benchmarks
Peer Average Claims93.0
Peer Average 30-Day Fills144.5
Peer Average Days Supply3,907
Conservative Utilization

This provider writes prescriptions for this formulation 40.9% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $41,222.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$749.51

State Avg Cost Per Claim

$773.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Furosemide

Generic Formulation: FurosemideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 19.0
Days Supply 493
IN State Average Benchmarks
Peer Average Claims97.0
Peer Average 30-Day Fills188.0
Peer Average Days Supply5,279
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 86.6% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $63.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.86

State Avg Cost Per Claim

$5.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.

Therapeutic Applications

Furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Furosemide is a water pill (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 32
30-Day Fills 66.8
Days Supply 1,985
IN State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills55.8
Peer Average Days Supply1,645
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $996.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.14

State Avg Cost Per Claim

$40.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 881
IN State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.7
Peer Average Days Supply841
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $466,919.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,061.92

State Avg Cost Per Claim

$14,932.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 59
30-Day Fills 148.0
Days Supply 4,440
IN State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills105.9
Peer Average Days Supply3,149
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 28.3% more claims than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,738.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$80.32

State Avg Cost Per Claim

$33.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Mekinist

Generic Formulation: Trametinib Dimethyl SulfoxideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 570
IN State Average Benchmarks
Peer Average Claims12.0
Peer Average 30-Day Fills12.9
Peer Average Days Supply385
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 58.3% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $179,975.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,472.42

State Avg Cost Per Claim

$13,705.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Trametinib is used to treat various cancers (such as skin, thyroid, lung, solid tumors). It belongs to a class of drugs known as kinase inhibitors. Trametinib works by slowing or stopping the growth of cancer cells.

Ninlaro

Generic Formulation: Ixazomib CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
IN State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.9
Peer Average Days Supply556
Conservative Utilization

This provider writes prescriptions for this formulation 36.8% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $177,237.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,769.77

State Avg Cost Per Claim

$13,107.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of cancer (multiple myeloma). It works by slowing or stopping the growth of cancer cells.

Ondansetron Odt

Generic Formulation: OndansetronSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 13.0
Days Supply 170
IN State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.7
Peer Average Days Supply287
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.0% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $304.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.37

State Avg Cost Per Claim

$23.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 52
30-Day Fills 68.5
Days Supply 1,804
IN State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills56.5
Peer Average Days Supply977
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $351.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.76

State Avg Cost Per Claim

$5.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 15.0
Days Supply 249
IN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills34.8
Peer Average Days Supply379
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.8% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $499.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$38.41

State Avg Cost Per Claim

$15.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Promacta

Generic Formulation: Eltrombopag OlamineSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
IN State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.5
Peer Average Days Supply494
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $83,288.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,940.67

State Avg Cost Per Claim

$14,316.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) or who have chronic hepatitis C. It may also be used to treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets.

Revlimid

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 420
IN State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills33.8
Peer Average Days Supply903
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.5% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $263,738.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,582.57

State Avg Cost Per Claim

$18,278.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Tafinlar

Generic Formulation: Dabrafenib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
IN State Average Benchmarks
Peer Average Claims12.0
Peer Average 30-Day Fills12.4
Peer Average Days Supply372
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 33.3% more claims than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $140,616.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,788.50

State Avg Cost Per Claim

$12,800.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dabrafenib is used to treat various cancers (such as skin, thyroid, lung, solid tumors). It belongs to a class of drugs known as kinase inhibitors. Dabrafenib works by slowing or stopping the growth of cancer cells.

Vijoice

Generic Formulation: AlpelisibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 308
IN State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$36,484.75

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer. Alpelisib may also be used to treat a certain overgrowth disorder, PIK3CA-Related Overgrowth Spectrum (PROS). Alpelisib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of certain abnormal cells that can cause cancer or PROS.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 40
30-Day Fills 80.0
Days Supply 2,400
IN State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills82.9
Peer Average Days Supply2,313
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $45,165.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,129.14

State Avg Cost Per Claim

$872.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
IN State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills34.0
Peer Average Days Supply1,020
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $177,105.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,100.51

State Avg Cost Per Claim

$12,934.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SUNIL BABU M.D. provides transparency into local medical care patterns within Fort Wayne, IN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.